Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩780,000.00
Day range
₩769,000.00 - ₩780,000.00
Year range
₩668,000.00 - ₩880,000.00
Market cap
54.80T KRW
Avg Volume
50.22K
P/E ratio
63.90
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 1.07T | 11.18% |
Operating expense | 178.55B | 20.21% |
Net income | 290.68B | -21.42% |
Net profit margin | 27.08 | -29.31% |
Earnings per share | 4.08K | -22.33% |
EBITDA | 491.91B | 21.39% |
Effective tax rate | 18.28% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.06T | -35.61% |
Total assets | 16.05T | -3.23% |
Total liabilities | 6.22T | -18.19% |
Total equity | 9.83T | — |
Shares outstanding | 71.17M | — |
Price to book | 5.65 | — |
Return on assets | 5.48% | — |
Return on capital | 7.45% | — |
Cash Flow
Net change in cash
| (KRW) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | 290.68B | -21.42% |
Cash from operations | 832.86B | 169.40% |
Cash from investing | -449.75B | -357.01% |
Cash from financing | -285.51B | -600.34% |
Net change in cash | 88.75B | -82.78% |
Free cash flow | 419.15B | 133.00% |
About
Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing services to the biopharmaceutical industry.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly and AstraZeneca. Samsung Biologics also partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax, during the COVID-19 pandemic. Wikipedia
CEO
Founded
2011
Website
Employees
4,284
